{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:17:58Z","timestamp":1782559078026,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antagonist pleiotropy, where a gene exerts a beneficial effect at early stages and a deleterious effect later on in an animal\u2019s life, may explain the evolutionary persistence of devastating genetic diseases such as Huntington\u2019s disease (HD). To date, however, there is little direct experimental evidence to support this theory. Here, we studied a transgenic mouse carrying the HD mutation with a repeat of 50 CAGs (R6\/2_50) that is within the pathological range of repeats causing adult-onset disease in humans. R6\/2_50 mice develop characteristic HD brain aggregate pathology, with aggregates appearing predominantly in the striatum and cortex. However, they show few signs of disease in their lifetime. On the contrary, R6\/2_50 mice appear to benefit from carrying the mutation. They have extended lifespans compared to wildtype (WT) mice, and male mice show enhanced fecundity. Furthermore, R6\/2_50 mice outperform WT mice on the rotarod and show equal or better performance in the two choice discrimination task than WT mice. This novel mouse line provides direct experimental evidence that, although the HD mutation causes a fatal neurodegenerative disorder, there may be premorbid benefits of carrying the mutation.<\/jats:p>","DOI":"10.1038\/s41598-018-37102-8","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T10:16:28Z","timestamp":1546596988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"given":"A. J.","family":"Morton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Skillings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. I.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"37102_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"37102_CR2","doi-asserted-by":"crossref","unstructured":"Bates, G., Tabrizi, S. & Jones, L. Eds Huntington\u2019s disease 4th Edn. (Oxford Univ. Press, Oxford, 2014).","DOI":"10.1093\/med\/9780199929146.001.0001"},{"key":"37102_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1558-5646.1957.tb02911.x","volume":"11","author":"GC Williams","year":"1957","unstructured":"Williams, G. C. Pleiotropy natural selection, and the evolution of senescence. Evolution 11, 398\u2013411 (1957).","journal-title":"Evolution"},{"key":"37102_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0162-3095(88)90027-1","volume":"9","author":"RL Albin","year":"1988","unstructured":"Albin, R. L. The pleiotropic gene theory of senescence: supportive evidence from human genetic disease. Ethol. Sociobiol. 9, 371\u2013382 (1988).","journal-title":"Ethol. Sociobiol."},{"key":"37102_CR5","unstructured":"Medawar, P. An Unsolved Problem of Biology. (Lewis, H. K. & Co., London, 1970)."},{"key":"37102_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/00048679109077743","volume":"25","author":"SA Pridmore","year":"1991","unstructured":"Pridmore, S. A. & Adams, G. C. The fertility of HD affected individuals in Tasmania. Aust. NZ J. Psychiat 25, 262\u20134 (1991).","journal-title":"Aust. NZ J. Psychiat"},{"key":"37102_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.mehy.2007.02.046","volume":"69","author":"B Eskenazi","year":"2007","unstructured":"Eskenazi, B., Wilson-Rich, N. & Starks, P. A Darwinian approach to Huntington\u2019s disease: subtle health benefits of a neurological disorders. Medical Hypotheses 69, 1183\u20131189 (2007).","journal-title":"Medical Hypotheses"},{"key":"37102_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF01436004","volume":"91","author":"RL Albin","year":"1993","unstructured":"Albin, R. L. Antagonistic pleiotropy, mutation accumulation, and human genetic disease. Genetica 91, 279\u2013286 (1993).","journal-title":"Genetica"},{"issue":"9","key":"37102_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ejhg.2016.13","volume":"24","author":"MS Thion","year":"2016","unstructured":"Thion, M. S. et al. CAG repeat size in Huntingtin alleles is associated with cancer prognosis. Eur. J. Hum. Genet. 24(9), 1310\u20135 (2016).","journal-title":"Eur. J. Hum. Genet."},{"issue":"12","key":"37102_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1212\/WNL.0000000000003725","volume":"88","author":"G Coarelli","year":"2017","unstructured":"Coarelli, G. et al. Low cancer prevalence in polyglutamine expansion diseases. Neurology 88(12), 1114\u20131119 (2017).","journal-title":"Neurology"},{"issue":"3","key":"37102_CR11","doi-asserted-by":"publisher","first-page":"e45336","DOI":"10.15252\/embr.201745336","volume":"19","author":"AE Murmann","year":"2018","unstructured":"Murmann, A. E. et al. Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells. EMBO Rep. 19(3), e45336 (2018).","journal-title":"EMBO Rep."},{"key":"37102_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1342::AID-CNCR33>3.0.CO;2-3","volume":"6","author":"SA Sorenson","year":"1999","unstructured":"Sorenson, S. A., Fenger, K. & Olsen, J. Significantly lower incidence of cancer among patients with Huntington\u2019s disease. Cancer 6, 1342\u20131346 (1999).","journal-title":"Cancer"},{"issue":"5","key":"37102_CR13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou, F. & Humbert, S. The biology of huntingtin. Neuron 89(5), 910\u201326 (2016).","journal-title":"Neuron"},{"issue":"2","key":"37102_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue. Nat. Genet. 11(2), 155\u201363 (1995).","journal-title":"Nat. Genet."},{"issue":"12","key":"37102_CR15","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl. Acad. Sci. USA 113(12), 3359\u201364 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"37102_CR16","first-page":"1833","volume":"24","author":"LH Rodan","year":"2016","unstructured":"Rodan, L. H. et al. A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene. Eur. J. Hum. Genet. 24(12), 1833 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"37102_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi, M. A., Morton, A. J. & Hayden, M. R. Choosing an animal model for the study of Huntington\u2019s disease. Nat. Rev. Neurosci. 14, 708\u2013721 (2013).","journal-title":"Nat. Rev. Neurosci."},{"issue":"11","key":"37102_CR18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.26006","volume":"29","author":"L Menalled","year":"2014","unstructured":"Menalled, L. & Brunner, D. Animal models of Huntington\u2019s disease for translation to the clinic: best practices. Mov. Disord. 29(11), 1375\u201390 (2014).","journal-title":"Mov. Disord."},{"issue":"15","key":"37102_CR19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/hmg\/ddh175","volume":"13","author":"G Schilling","year":"2004","unstructured":"Schilling, G. et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington\u2019s disease-like phenotypes in transgenic mice. Hum. Mol. Genet. 13(15), 1599\u2013610 (2004).","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"37102_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/hmg\/8.5.763","volume":"8","author":"PF Shelbourne","year":"1999","unstructured":"Shelbourne, P. F. et al. A Huntington\u2019s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8(5), 763\u201374 (1999).","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"37102_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nbd.2008.11.015","volume":"33","author":"AJ Morton","year":"2009","unstructured":"Morton, A. J. et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6\/2 mice. Neurobiol. Dis. 33(3), 331\u201341 (2009).","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"37102_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2337\/diabetes.48.3.649","volume":"48","author":"MS Hurlbert","year":"1999","unstructured":"Hurlbert, M. S. et al. Mice transgenic for an expanded CAG repeat in the Huntington\u2019s disease gene develop diabetes. Diabetes 48(3), 649\u201351 (1999).","journal-title":"Diabetes"},{"issue":"2","key":"37102_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","volume":"166","author":"MJ Hunt","year":"2005","unstructured":"Hunt, M. J. & Morton, A. J. Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington\u2019s disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 166(2), 220\u20139 (2005).","journal-title":"Exp. Brain Res."},{"issue":"5334","key":"37102_CR24","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334), 1990\u20133 (1997).","journal-title":"Science"},{"issue":"3","key":"37102_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/NEN.0b013e318198d320","volume":"68","author":"ES Herndon","year":"2009","unstructured":"Herndon, E. S. et al. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J Neuropathol Exp Neurol. 68(3), 250\u201361 (2009).","journal-title":"J Neuropathol Exp Neurol."},{"key":"37102_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1023\/A:1010887421592","volume":"29","author":"AJ Morton","year":"2000","unstructured":"Morton, A. J., Lagan, M. A., Skepper, J. N. & Dunnett, S. B. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington\u2019s disease mutation. J. Neurocyt. 29, 681\u2013705 (2000).","journal-title":"J. Neurocyt."},{"key":"37102_CR27","doi-asserted-by":"publisher","first-page":"e41450","DOI":"10.1371\/journal.pone.0041450","volume":"7","author":"B Gong","year":"2012","unstructured":"Gong, B., Kielar, C. & Morton, A. J. Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington\u2019s disease mutation. Plos One 7, e41450 (2012).","journal-title":"Plos One"},{"issue":"1","key":"37102_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cne.10776","volume":"465","author":"LB Menalled","year":"2003","unstructured":"Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S. & Chesselet, M. F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats. J Comp Neurol. 465(1), 11\u201326 (2003).","journal-title":"J Comp Neurol."},{"issue":"4","key":"37102_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.neuroscience.2004.10.037","volume":"131","author":"SJ Tallaksen-Greene","year":"2005","unstructured":"Tallaksen-Greene, S. J., Crouse, A. B., Hunter, J. M., Detloff, P. J. & Albin, R. L. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience 131(4), 843\u201352 (2005).","journal-title":"Neuroscience"},{"issue":"15","key":"37102_CR30","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/hmg\/ddm133","volume":"16","author":"A Kuhn","year":"2007","unstructured":"Kuhn, A. et al. Mutant huntingtin\u2019s effects on striatal gene expression in mice recapitulate changes observed in human Huntington\u2019s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16(15), 1845\u201361 (2007).","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"37102_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-140116","volume":"4","author":"M Wegrzynowicz","year":"2015","unstructured":"Wegrzynowicz, M. et al. Novel BAC mouse model of Huntington\u2019s disease with 225 CAG repeats exhibits an early widespread and stable degenerative phenotype. J. Huntingtons Dis. 4(1), 17\u201336 (2015).","journal-title":"J. Huntingtons Dis."},{"issue":"2","key":"37102_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/2510","volume":"20","author":"PH Reddy","year":"1998","unstructured":"Reddy, P. H. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 20(2), 198\u2013202 (1998).","journal-title":"Nat Genet."},{"issue":"4","key":"37102_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ng1297-404","volume":"17","author":"JK White","year":"1997","unstructured":"White, J. K. et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion. Nat Genet. 17(4), 404\u201310 (1997).","journal-title":"Nat Genet."},{"issue":"6","key":"37102_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/hmg\/ddg075","volume":"12","author":"S von H\u00f6rsten","year":"2003","unstructured":"von H\u00f6rsten, S. et al. Transgenic rat model of Huntington\u2019s disease. Hum Mol Genet. 12(6), 617\u201324 (2003).","journal-title":"Hum Mol Genet."},{"key":"37102_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fnins.2018.00011","volume":"12","author":"AC Plank","year":"2018","unstructured":"Plank, A. C. et al. Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAG(n51trunc) Model of Huntington Disease. Front Neurosci. 12, 11 (2018).","journal-title":"Front Neurosci."},{"issue":"21","key":"37102_CR36","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1093\/hmg\/ddl394","volume":"15","author":"HP Nguyen","year":"2006","unstructured":"Nguyen, H. P. et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington\u2019s disease. Hum Mol Genet. 15(21), 3177\u201394 (2006).","journal-title":"Hum Mol Genet."},{"issue":"1","key":"37102_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nlm.2010.11.010","volume":"95","author":"A Faure","year":"2011","unstructured":"Faure, A. et al. Altered emotional and motivational processing in the transgenic rat model for Huntington\u2019s disease. Neurobiol Learn Mem. 95(1), 92\u2013101 (2011).","journal-title":"Neurobiol Learn Mem."},{"key":"37102_CR38","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.1073\/pnas.96.15.8727","volume":"96","author":"O Hansson","year":"1999","unstructured":"Hansson, O. et al. Transgenic mice expressing a Huntington\u2019s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 96, 8727\u20138732 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"37102_CR39","doi-asserted-by":"crossref","unstructured":"MacGibbon, G. A. et al. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington\u2019s disease transgenic mice. J. Neurosci. Res. 67(3), 372\u20138 (2002).","DOI":"10.1002\/jnr.10100"},{"issue":"1","key":"37102_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0361-9230(00)00238-0","volume":"52","author":"AJ Morton","year":"2000","unstructured":"Morton, A. J. & Leavens, W. Mice transgenic for the human Huntington\u2019s disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res. Bull. 52(1), 51\u20139 (2000).","journal-title":"Brain Res. Bull."},{"issue":"5","key":"37102_CR41","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1046\/j.1471-4159.2000.0752163.x","volume":"75","author":"MA Hickey","year":"2000","unstructured":"Hickey, M. A. & Morton, A. J. Mice transgenic for the Huntington\u2019s disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J. Neurochem. 75(5), 2163\u201371 (2000).","journal-title":"J. Neurochem."},{"issue":"9","key":"37102_CR42","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1046\/j.0953-816x.2001.01767.x","volume":"14","author":"O Hansson","year":"2001","unstructured":"Hansson, O. et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioral deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 14(9), 1492\u2013504 (2001).","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"37102_CR43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1046\/j.1471-4159.2001.00482.x","volume":"78","author":"O Hansson","year":"2001","unstructured":"Hansson, O. et al. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington\u2019s disease is dependent on age and CAG repeat length. J. Neurochem. 78(4), 694\u2013703 (2001).","journal-title":"J. Neurochem."},{"issue":"2","key":"37102_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1152\/jn.00483.2004","volume":"93","author":"GJ Klapstein","year":"2005","unstructured":"Klapstein, G. J. & Levine, M. S. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington\u2019s disease R6\/2 transgenic mice. J. Neurophysiol. 93(2), 758\u201365 (2005).","journal-title":"J. Neurophysiol."},{"issue":"2","key":"37102_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0304-3940(02)01111-4","volume":"334","author":"J Schiefer","year":"2002","unstructured":"Schiefer, J. et al. Huntington\u2019s disease transgenic mice are resistant to global cerebral ischemia. Neurosci. Lett. 334(2), 99\u2013102 (2002).","journal-title":"Neurosci. Lett."},{"issue":"Pt 3","key":"37102_CR46","first-page":"505","volume":"127","author":"BR Jarabek","year":"2004","unstructured":"Jarabek, B. R., Yasuda, R. P. & Wolfe, B. B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington\u2019s mouse model. Brain 127(Pt 3), 505\u201316 (2004).","journal-title":"Brain"},{"issue":"6","key":"37102_CR47","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","volume":"125","author":"RK Graham","year":"2009","unstructured":"Graham, R. K. et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125(6), 1179\u201391 (2009).","journal-title":"Cell"},{"issue":"2","key":"37102_CR48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JHD-129005","volume":"1","author":"MK Strong","year":"2012","unstructured":"Strong, M. K. et al. Age-dependent resistance to excitotoxicity in Htt CAG140 mice and the effect of strain background. J. Huntingtons Dis. 1(2), 221\u201341 (2012).","journal-title":"J. Huntingtons Dis."},{"issue":"9","key":"37102_CR49","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1046\/j.0953-816x.2001.01765.x","volume":"14","author":"A Peters\u00e9n","year":"2001","unstructured":"Peters\u00e9n, A. et al. Mice transgenic for exon 1 of the Huntington\u2019s disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur. J. Neurosci 14(9), 1425\u201335 (2001).","journal-title":"Eur. J. Neurosci"},{"issue":"3","key":"37102_CR50","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.cdd.4402261","volume":"15","author":"T Zuchner","year":"2008","unstructured":"Zuchner, T. & Brundin, P. Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ. 15(3), 435\u201342 (2008).","journal-title":"Cell Death Differ."},{"issue":"11","key":"37102_CR51","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/cdd.2013.66","volume":"20","author":"G Kreiner","year":"2013","unstructured":"Kreiner, G. et al. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ. 20(11), 1455\u201364 (2013).","journal-title":"Cell Death Differ."},{"issue":"2","key":"37102_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1172\/JCI82670","volume":"126","author":"JR Naranjo","year":"2016","unstructured":"Naranjo, J. R. et al. Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. J. Clin. Invest. 126(2), 627\u201338 (2016).","journal-title":"J. Clin. Invest."},{"key":"37102_CR53","unstructured":"Kudwa, A. E. et al. Increased body weight of the BAC HD transgenic mouse Model of Huntington\u2019s disease accounts for some but not all of the observed HD-like motor deficits. Plos Curr. 5, ecurrents.hd.0ab4f3645aff523c56ecc8ccbe41a198 (2013)."},{"key":"37102_CR54","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/hmg\/ddq026","volume":"19","author":"MA Pouladi","year":"2010","unstructured":"Pouladi, M. A. et al. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet. 19, 1528\u201338 (2010).","journal-title":"Hum Mol Genet."},{"issue":"6","key":"37102_CR55","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","volume":"85","author":"A Dedeoglu","year":"2003","unstructured":"Dedeoglu, A. et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice. J. Neurochem. 85(6), 1359\u201367 (2003).","journal-title":"J. Neurochem."},{"issue":"4","key":"37102_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","volume":"61","author":"NI Wood","year":"2003","unstructured":"Wood, N. I. & Morton, A. J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington\u2019s disease mutation. Brain Res. Bull. 61(4), 375\u201383 (2003).","journal-title":"Brain Res. Bull."},{"issue":"8","key":"37102_CR57","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/archneur.1991.00530200036015","volume":"48","author":"RH Myers","year":"1991","unstructured":"Myers, R. H. et al. Factors associated with slow progression in Huntington\u2019s disease. Arch. Neurol. 48(8), 800\u20134 (1991).","journal-title":"Arch. Neurol."},{"issue":"3","key":"37102_CR58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.25007","volume":"82","author":"JMM van der Burg","year":"2017","unstructured":"van der Burg, J. M. M. et al. Body weight is a robust predictor of clinical progression in Huntington disease. Ann Neurol. 82(3), 479\u2013483 (2017).","journal-title":"Ann Neurol."},{"key":"37102_CR59","unstructured":"Balci, F. et al. High-throughput automated phenotyping of two genetic mouse models of Huntington\u2019s disease. Plos Curr. 5, ecurrents.hd.124aa0d16753f88215776fba102ceb29 (2013)."},{"issue":"20","key":"37102_CR60","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.cub.2012.08.012","volume":"22","author":"C Beste","year":"2012","unstructured":"Beste, C., Wascher, E., Dinse, H. R. & Saft, C. Faster perceptual learning through excitotoxic neurodegeneration. Curr. Biol. 22(20), 1914\u20137 (2012).","journal-title":"Curr. Biol."},{"issue":"23","key":"37102_CR61","doi-asserted-by":"publisher","first-page":"10428","DOI":"10.1523\/JNEUROSCI.19-23-10428.1999","volume":"19","author":"LA Lione","year":"1999","unstructured":"Lione, L. A. et al. Selective discrimination learning impairments in mice expressing the human Huntington\u2019s disease mutation. J. Neurosci. 19(23), 10428\u201337 (1999).","journal-title":"J. Neurosci."},{"key":"37102_CR62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1399-0004.1975.tb00341.x","volume":"7","author":"M Shokeir","year":"1975","unstructured":"Shokeir, M. Investigation on Huntington\u2019s Disease in the Canadian Prairies. II. Fecundity and fitness. Clin. Genet. 7, 349\u2013353 (1975).","journal-title":"Clin. Genet."},{"issue":"4","key":"37102_CR63","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng0894-525","volume":"7","author":"DC Rubinsztein","year":"1994","unstructured":"Rubinsztein, D. C. Mutational bias provides a model for the evolution of Huntington\u2019s disease and predicts a general increase in disease prevalence. Nat. Genet. 7(4), 525\u201330 (1994).","journal-title":"Nat. Genet."},{"issue":"2","key":"37102_CR64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins, M. D. et al. The prevalence of Huntington\u2019s disease. Neuroepidemiology 46(2), 144\u201353 (2016).","journal-title":"Neuroepidemiology"},{"issue":"2","key":"37102_CR65","doi-asserted-by":"publisher","first-page":"e009070","DOI":"10.1136\/bmjopen-2015-009070","volume":"6","author":"NS Wexler","year":"2016","unstructured":"Wexler, N. S. et al. Incidence of adult Huntington\u2019s disease in the UK: a UK-based primary care study and a systematic review. BMJ Open 6(2), e009070 (2016).","journal-title":"BMJ Open"},{"issue":"2","key":"37102_CR66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/emmm.201201546","volume":"5","author":"C Moreira Sousa","year":"2013","unstructured":"Moreira Sousa, C. et al. The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2\/HER2 signalling. EMBO Mol. Med. 5(2), 309\u201325 (2013).","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"37102_CR67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby, S. C. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet. 84(3), 351\u201366 (2009).","journal-title":"Am J Hum Genet."},{"issue":"6","key":"37102_CR68","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajhg.2009.11.002","volume":"85","author":"D Falush","year":"2009","unstructured":"Falush, D. Haplotype background, repeat length evolution, and Huntington\u2019s disease. Am J Hum Genet. 85(6), 939\u201342 (2009).","journal-title":"Am J Hum Genet."},{"issue":"2","key":"37102_CR69","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1086\/318193","volume":"68","author":"D Falush","year":"2001","unstructured":"Falush, D., Almqvist, E. W., Brinkmann, R. R., Iwasa, Y. & Hayden, M. R. Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am J Hum Genet. 68(2), 373\u201385 (2001).","journal-title":"Am J Hum Genet."},{"issue":"1\u20132","key":"37102_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2010.08.024","volume":"298","author":"M Ma","year":"2010","unstructured":"Ma, M. et al. Evidence for a predisposing background for CAG expansion leading to HTT mutation in a Chinese population. J Neurol Sci. 298(1\u20132), 57\u201360 (2010).","journal-title":"J Neurol Sci."},{"issue":"3","key":"37102_CR71","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajmg.b.32618","volume":"177","author":"C Kay","year":"2018","unstructured":"Kay, C. et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. Am J Med Genet B Neuropsychiatr Genet. 177(3), 346\u2013357 (2018).","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"issue":"6137","key":"37102_CR72","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/329289a0","volume":"329","author":"JI Rotter","year":"1987","unstructured":"Rotter, J. I. & Diamond, J. M. What maintains the frequencies of human genetic diseases? Nature 329(6137), 289\u201390 (1987).","journal-title":"Nature"},{"key":"37102_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-160","volume":"12","author":"AJ Carter","year":"2011","unstructured":"Carter, A. J. & Nguyen, A. Q. Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. BMC Med. Genet. 12, 160, https:\/\/doi.org\/10.1186\/1471-2350-12-160 (2011).","journal-title":"BMC Med. Genet."},{"key":"37102_CR74","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/331666b0","volume":"331","author":"J Diamond","year":"1988","unstructured":"Diamond, J. Tay-Sachs carriers and tuberculosis resistance. Nature 331, 666\u2013667 (1988).","journal-title":"Nature"},{"issue":"R1","key":"37102_CR75","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser, M. S., Kordasiewicz, H. B. & McBride, J. L. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum. Mol. Genet. 25(R1), R53\u201364 (2016).","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"37102_CR76","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"Aronin, N. & DiFiglia, M. Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord. 29(11), 1455\u201361 (2014).","journal-title":"Mov Disord."},{"key":"37102_CR77","doi-asserted-by":"publisher","unstructured":"Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci Transl Med. 10(461) Figshare, https:\/\/doi.org\/10.1126\/scitranslmed.aar3959 (2018).","DOI":"10.1126\/scitranslmed.aar3959"},{"issue":"2","key":"37102_CR78","doi-asserted-by":"publisher","first-page":"e17119","DOI":"10.1371\/journal.pone.0017119","volume":"6","author":"D Duzdevich","year":"2011","unstructured":"Duzdevich, D. et al. Unusual structures are present in DNA fragments containing super-long Huntingtin CAG repeats. Plos One 6(2), e17119 (2011).","journal-title":"Plos One"},{"key":"37102_CR79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jneumeth.2015.07.016","volume":"265","author":"D Glynn","year":"2016","unstructured":"Glynn, D., Skillings, E. A. & Morton, A. J. A comparison of discrimination learning in touchscreen and 2-choice swim tank using an allelic series of Huntington\u2019s disease mice. J. Neurosci. Meth. 265, 56\u201371 (2016).","journal-title":"J. Neurosci. Meth."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37102-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T04:41:20Z","timestamp":1671252080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["37102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-37102-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"3 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"37"}}